Litcius/Paper detail

Microbial Biosurfactants: Antimicrobial Agents Against Pathogens

Albert Donald Luong, Maruthapandi Moorthy, John HT Luong

2026Macromol—A Journal of Macromolecular Research6 citationsDOIOpen Access PDF

Abstract

Microbial biosurfactants (mBSs) are bioactive molecules with diverse applications, notably as antimicrobial agents against antibiotic-resistant pathogens. Produced by bacteria and yeasts, mBSs are classified as glycolipids, lipopeptides, polymeric, and particulate types. The global rise in multidrug-resistant organisms, such as Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium, Pseudomonas aeruginosa, and Acinetobacter baumannii, underscores the urgent need for new antimicrobial strategies. mBSs disrupt microbial growth by interacting with the lipid components of pathogens, offering promising alternatives to conventional antibiotics. This review highlights the sources, chemical structures, and properties of mBSs, their antimicrobial activities, synergistic effects with antibiotics, and structure–activity relationships. Special emphasis is placed on surfactant modification, where targeted changes—such as valine substitution in surfactin—significantly lower critical micelle concentrations (CMC) and enhance antimicrobial potency. Such rational engineering demonstrates how biosurfactants can be tailored for improved biomedical performance while minimizing cytotoxicity. In parallel, artificial intelligence (AI) algorithms, including artificial neural networks and genetic algorithms, optimize yields, predict substrate suitability from agricultural residues, and guide microbial strain engineering. AI models can predict interfacial behavior and synchronize fermentation with purification. Advancing the understanding of mBS interactions with microbial membranes, combined with modification strategies and AI-guided optimization, is essential for developing targeted therapies against resistant infections. Future research should integrate these approaches to engineer novel derivatives, reduce costs, and validate clinical potential through comprehensive in vivo studies.

Topics & Concepts

AntimicrobialBiochemical engineeringBiotechnologyEscherichia coliComputational biologyBiologyAntimicrobial peptidesBacteriaDrug discoveryQuorum sensingChemistryAnti-Infective AgentsMicrobiologyAcinetobacterFlexibility (engineering)Pseudomonas aeruginosaAntimicrobial drugRational designSalmonellaMicrobial bioremediation and biosurfactantsBacterial biofilms and quorum sensingCancer Research and Treatments